What is ARTISTRY-6?
ARTISTRY-6 is a research study for adult patients with advanced cutaneous melanoma or advanced mucosal melanoma that is inoperable or has spread, and who have received prior treatment with an anti-programmed death-ligand 1 (anti-PD(L)1) therapy.
This study is testing an investigational treatment called nemvaleukin alfa (nemvaleukin). Nemvaleukin is investigational and not approved by any regulatory authority.
ARTISTRY-6 is being funded by the pharmaceutical company Mural Oncology.
What is the purpose of this research?
The purpose of ARTISTRY-6 is to assess the safety and efficacy of investigational nemvaleukin as a treatment for advanced or metastatic (cancer that has spread) or inoperable cutaneous and mucosal melanoma following prior anti-PD-(L)-1 therapy.
A study investigator and staff will determine eligibility on an individual basis, beginning with the criteria listed here.
To be eligible, a participant must meet the following criteria:
- Is 18 years of age or older
- Has a diagnosis of advanced cutaneous melanoma or advanced mucosal melanoma that is inoperable or has spread
- Has received prior treatment with an anti-PD-[L]-1 therapy, with or without an anti-CTLA4 drug, and no more than one other prior treatment (e.g., targeted therapy or chemotherapy)
- Has not received similar medications in the past
- Additional criteria may apply
Information About Treatment
This research study is enrolling participants in two treatment groups. Eligible participants will be assigned to a group based on his or her cancer type.
The medicine used in this study will be administered by an intravenous (IV, meaning through a person's veins) infusion.
Cutaneous Melanoma Group
Participants will receive a 30-minute intravenous infusion of nemvaleukin once every 21 days or twice every 21 days
Mucosal Melanoma Group
Participants will receive a 30-minute intravenous infusion of nemvaleukin daily for 5 consecutive days